Study of DM5167 in Patients With Advanced Solid Tumors

Summary

DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety. The aim of the study is to assess the safety and tolerability of DM5167 in patients with advanced solid tumors not respond to other treatments.

Timeline

Start

2024-10-24

Primary completion

2026-10-30

Completion

2027-01-31

Drugs

Indications